Deepika Jaiswal

Deepika Jaiswal

Auto-generated profile, based on publicly available information

Deepika Jaiswal

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2025 in Science Immunology
Verified
Journal Article
Closed access
SMSameer Kumar Malladi
Sameer Kumar Malladi
DJDeepika Jaiswal
Deepika Jaiswal
BYBaoling Ying
Baoling Ying
WAWafaa B. Alsoussi
Wafaa B. Alsoussi
TDTamarand L. Darling
Tamarand L. Darling
AEAli Ellebedy
Ali Ellebedy
Germinal centers (GCs) are key sites for antibody diversification and affinity maturation. SARS-CoV-2 messenger RNA (mRNA) vaccines elicit robust GC B cell responses in humans, but how these responses influence the breadth of immunity against viral variants remains unclear. We analyzed GC B cell responses in nine healthy adults after mRNA booster immunization. We show that 77.8% of the B cell clones in the GC expressed representative monoclonal antibodies (mAbs) recognizing the spike protein, with 37.8% of these targeting the receptor binding domain (RBD). One RBD-targeting mAb, mAb-52, neutralized all tested SARS-CoV-2 strains, including the recent XEC variant. mAb-52 used the IGHV3-66 public clonotype, protected hamsters challenged against the EG.5.1 variant, and targeted the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Its broad reactivity was driven by extensive somatic hypermutation, underscoring the critical role of GC reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.

15 July 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
ZMZaid Kamal Madni
Zaid Kamal Madni
AKAmit Kumar
Amit Kumar
UKUjjwal Kumar
Ujjwal Kumar
DJDeepika Jaiswal
Deepika Jaiswal
DSDinakar M Salunke
Dinakar M Salunke
Nonspecific lipid transfer proteins are multifunctional and multispecific seed proteins with a characteristic hydrophobic cavity that runs form N-terminal to the C-terminal end. They are capable of binding and transferring different lipid molecules by means of their hydrophobic cavity. Apart from the cavity, lipid molecules bind and interact at key positions on the nsLTP surface as well. The plasticity of the hydrophobic cavity is an unusual property, considered as the primary lipid binding site. Here, we report a crystal structure of nsLTP from Solanum melongena with two lauric acid molecules bound inside the cavity. It has been observed that the extent of the N-terminal entry point and plasticity of the cavity can be extended, upon binding of one or two lipid molecules inside the cavity. The MD simulation further revealed that the lipid molecule shows high mobility inside the cavity and interestingly, was able to change its orientation. An alternate lipid entry site adjacent to the N-terminal end was uncovered during simulation and Arg-84 was implicated to be a potential regulatory residue aside from Tyr-59. Collectively, this study helps to understand that changes in orientation of the lipid inside the cavity could occur intermittently besides entering the cavity via tail-in-mechanism. Communicated by Ramaswamy H. Sarma


9 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSameer Kumar Malladi
Sameer Kumar Malladi
DJDeepika Jaiswal
Deepika Jaiswal
BYBaoling Ying
Baoling Ying
WAWafaa B. Alsoussi
Wafaa B. Alsoussi
TDTamarand L. Darling
Tamarand L. Darling
AEAli Ellebedy
Ali Ellebedy
SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. It remains unclear how the continuous evolution of the virus impacts the breadth of the induced GC B cell response. Using ultrasound-guided fine needle aspiration, we examined draining lymph nodes of nine healthy adults following bivalent booster immunization. We show that 77.8% of the B cell clones in the GC expressed as representative monoclonal antibodies recognized the spike protein, with a third (37.8%) of these targeting the receptor binding domain (RBD). Strikingly, only one RBD-targeting mAb, mAb-52, neutralized all tested SARS- CoV-2 strains, including the recent KP.2 variant. mAb-52 utilizes the IGHV3-66 public clonotype, protects hamsters challenged against the EG.5.1 variant and targets the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Finally, we show that the remarkable breadth of mAb-52 is due to the somatic hypermutations accumulated within vaccine-induced GC reaction. One Sentence Summary Booster SARS-CoV-2 mRNA vaccine recruits and broadens GC B cell responses targeting a highly conserved site on receptor binding domain of spike glycoprotein.

16 July 2025 in bioRxiv
Verified
Preprint
Open access
DJDeepika Jaiswal
Deepika Jaiswal
SVSheenam Verma
Sheenam Verma
ZMZaid K Madni
Zaid K Madni
GKGagandeep Kaur
Gagandeep Kaur
KKKanwal J Kaur
Kanwal J Kaur
DSDinakar M. Salunke
Dinakar M. Salunke
HIV-1 escape from neutralizing antibodies even in the presence of strong host immunity is associated with variations in envelope proteins that drive antigenic diversification. The virus exploits the error-prone nature of reverse transcriptase and the high mutation rate as key survival strategies. However, the rate of production of new variations occurs at relatively slow pace. Interestingly, the immune system often produces cross-reactive antibodies, with anticipated role in neutralizing point mutations in HIV surface proteins by cross-reacting with mutants and tolerating them. In light of this paradox, we explored the mystery of immune evasion and antibody promiscuity by screening single chain variable fragment (scFvs) antibodies against several crucial HIV-1 gp41 epitopes using a phage display library. These findings underscore the broader significance of cross-reactive antibodies. Here, high-affinity cross-reactive scFvs showed physiologically relevant affinities with peptide epitopes, their analogs, and the native HIV-1 gp41 protein. We determined the crystal structure of a high-affinity cross-reactive scFv, DE94, and obtained insights into the molecular interactions of scFv antibodies with peptide epitopes and its natural mutants using molecular docking studies. This analysis of cross-reactive antibodies could contribute to the therapeutic development against immune-evading pathogens and paves the way for innovative strategies for combating viral infections, including emerging global threats.